ImpediMed (IPD) Q1 2027 earnings summary

Executive summary

• Q1 FY27 revenue was $3.8m, up 6% QoQ; ARR was $14.9m, up 3% QoQ, and $16.1m in constant currency, up 12% YoY.

• Operating cash outflow was $2.462m, down $2.4m QoQ; quarter-end cash was $11.579m, equal to 4.7 quarters of operating cash flow.

• BCRL sales missed expectations; sales leadership changed and the team is being rebuilt as expanded clinical applications and care standards support longer-term growth.

Financial highlights

• Revenue was $3.8m, up 6% QoQ; customer receipts were $4.2m vs $4.3m in Q4 FY26.

• Core Business TCV was $4.4m vs $5.4m in Q4 FY26, mainly due to fewer contracts up for renewal; renewed contract prices rose 18% on average.

• ARR was $14.9m, up $0.5m or 3% QoQ; constant-currency ARR was $16.1m, up $1.7m or 12% YoY.

• 47 SOZO units sold globally: 28 in the U.S. and 19 in ROW; patient tests totaled 94,000, up 8% QoQ and 22% YoY.

Outlook and guidance

• Q2 priorities include filling U.S. sales roles, progressing the pipeline, targeting NAPBC opportunities, and expanding customer programs.

• Growth actions include advancing oncology partnerships, using a KOL partnership in Longevity & Wellness, and generating leads at sector conferences.

• Heart Health priorities include supporting studies and securing a medical-device collaboration; investment will remain paced to commercial traction.

• Sales-team hiring and productivity ramp may affect cash-flow breakeven timing; initiatives to mitigate the impact are being evaluated.